Camena Bioscience

#Antibodies #Antibody discovery workflow #Camena Bioscience

Camena appoints CEO to scale antibody discovery platform 

Camena Bioscience has appointed Gregory McGuinness as CEO as it looks to scale its antibody discovery platform.  The biotechnology company, which sees itself as a pioneer in enzymatic DNA synthesis for AI-driven antibody discovery, has appointed McGuinness to support the company’s growth, including its commercialisation of AI-driven antibody… Read More

#News

#Camena Bioscience #Financing #Funding #Genetics / genomics #Synthetic biology

Synthetic biology company raises $10m in financing round

Camena Bioscience has closed a $10m Series A financing round, which will be used to scale operations and continue development of DNA synthesis platform gSynth. Synthetic genes are widely used by researchers to understand the mechanisms of disease, and in the drug discovery process to combat… Read More

#News